Group 1 - Zhejiang Apac Pharmaceutical Co., Ltd. reported non-operating fund occupation by related parties, with a total of 7,157.81 million yuan as of June 2025 [1][2] - The company has a significant amount of receivables from its wholly-owned subsidiaries, including Shaoxing Yatai Pharmaceutical Co., Ltd. and Shaoxing Yatai Medical Technology Co., Ltd., amounting to 7,007.81 million yuan and 150.00 million yuan respectively [1][2] - The total amount of non-operating fund occupation is expected to be repaid, with a cumulative repayment of 7,014.87 million yuan noted [2] Group 2 - The company has engaged in operational transactions with related parties, including management fees paid to Ningbo Dadi Chemical Environmental Protection Co., Ltd., totaling 6.80 million yuan [2] - The financial data indicates a stable relationship with its subsidiaries, as evidenced by the ongoing transactions and receivables [1][2] - The company’s financial management is overseen by its legal representative and accounting personnel, ensuring compliance and accuracy in financial reporting [2]

Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a significant decline in revenue and net profit for the first half of 2025, primarily due to intensified market competition and the impact of centralized drug procurement policies [5][10]. Company Overview and Financial Indicators - The company’s total revenue for the reporting period was approximately CNY 152.07 million, a decrease of 31.48% compared to the same period last year [5][10]. - The net profit attributable to shareholders was approximately CNY -48.86 million, reflecting a decline of 524.31% year-on-year [5][10]. - The company plans not to distribute cash dividends or issue bonus shares [1]. Industry Analysis - The pharmaceutical industry is characterized by weak cyclicality, high investment, high risk, and strict regulation, making it a strategic emerging industry crucial for national health and safety [6][7]. - The industry is experiencing profound changes due to ongoing healthcare reforms, which have significantly altered the competitive landscape, particularly in terms of drug quality and pricing strategies [6][7]. - The demand for pharmaceuticals is expected to continue growing due to factors such as an aging population, rising chronic disease rates, and increased health awareness among residents [6][7]. Business Operations - The company focuses on the manufacturing of pharmaceuticals, including both antibiotic and non-antibiotic products, with a total of 114 approved formulations [8][9]. - The sales strategy includes establishing a comprehensive marketing network that extends to various healthcare institutions and pharmacies, transitioning from traditional marketing to more specialized academic marketing [9][10]. Performance Drivers - The decline in revenue is attributed to intensified competition and the effects of centralized procurement policies, which have pressured sales [10][11]. - The company’s financial expenses increased significantly due to the redemption of convertible bonds, which were due in April 2025 [10][11]. - Investment income surged by 923.49% due to the sale of a subsidiary, indicating a shift in profit sources [10][12].

Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a significant decline in revenue while achieving a substantial increase in net profit for the first half of 2025, indicating a shift in financial performance dynamics [1][2]. Financial Performance - The company's operating revenue for the reporting period was CNY 152.07 million, a decrease of 31.48% compared to CNY 221.93 million in the same period last year [1]. - Net profit attributable to shareholders reached CNY 105.18 million, marking an increase of 1,820.97% from CNY 5.48 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was CNY -48.86 million, a decline of 524.31% compared to CNY -7.83 million in the same period last year [1]. - The basic earnings per share rose to CNY 0.14, up 1,300% from CNY 0.01 [1]. - The weighted average return on equity was 10.01%, compared to 0.94% in the previous year [1]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.24 billion, down 11.35% from CNY 1.40 billion at the end of the previous year [1]. - The net assets attributable to shareholders were CNY 1.13 billion, an increase of 16.15% from CNY 972.18 million [2]. - The debt-to-asset ratio improved to 9.14% from 30.65% in the previous year [3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,101 [2]. - Ningbo Fubon Holdings Group Co., Ltd. remained the controlling shareholder with an 11.99% stake [2]. Significant Events - The company completed the sale of its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., for a total consideration of CNY 175 million, which included the assumption of debts [4][5]. - The first payment of CNY 30 million was received on March 31, 2025, and the second payment of CNY 145 million was received on June 25, 2025 [5].

Core Viewpoint - The company reported a significant decline in revenue while achieving a remarkable increase in net profit due to asset disposal [1] Financial Performance - The company achieved an operating revenue of 152 million yuan in the first half of the year, representing a year-on-year decrease of 31.48% [1] - The net profit attributable to shareholders was 105 million yuan, showing a year-on-year increase of 1820.97% [1] Asset Disposal - The report period included a non-current asset disposal gain of 149 million yuan, primarily from the sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd. [1]

浙江亚太药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：浙江亚太药业股份有限公司 单位：万元 | | | 占用方与 | 上市公司 | 2025 | 年期初 | 2025 年半年 | 2025 年半 | 2025 年半年 | 2025 年 6 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | | 上市公司 | | | | 度占用累计 | 年度占用 | | | 占用形 | | | | 资金占用方名称 | | 核算的会 | 占用资金余 | | | | 度偿还累计 | 末占用资金 | | 占用性质 | | 用 | | 的关联关 | | | | 发生金额（不 | 资金的利 | | | 成原因 | | | | | | 计科目 | 额 | | | | 发生金额 | 余额 | | | | | | 系 | | | | 含利息） | 息（如有） | | | | | | 控股股东、实际控 制人及其附属企 | | | | | | | | | | | | ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-068 1 单位：元 项目 计提金额 一、信用减值损失(损失以"-"号填列） 其中：应收账款信用减值损失 -230,649.18 其他应收款信用减值损失 1,095,811.38 二、资产减值损失(损失以"-"号填列） | 其中：存货跌价损失 | -5,029,349.00 | | --- | --- | | 合计 | -4,164,186.80 | 二、本次计提信用减值损失、资产减值损失对公司的影响 浙江亚太药业股份有限公司 关于计提信用减值损失、资产减值损失的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"或"亚太药 业"）于 2025 年 8 月 28 日召开第八届董事会第四次会议、第八 届监事会第四次会议，审议通过了《关于计提信用减值损失、资 产减值损失的议案》，现将具体情况公告如下： 一、本次计提信用减值损失、资产减值损失的情况概述 根据《企业会计准则》及《深圳证券交易所上市公司自律监 管指引第 1 号—主板上市公司规范运作》等相关规定的要 ...

浙江亚太药业股份有限公司 2025 年半年度财务报告 浙江亚太药业股份有限公司 2025 年半年度财务报告 2025 年 08 月 浙江亚太药业股份有限公司 2025 年半年度财务报告 浙江亚太药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：浙江亚太药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 625,177,565.07 | 743,850,694.68 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 96,912,265.35 | 95,309,526.30 | | 应收款项融资 | 35,415,795.84 | 16,367,501.71 | | 预付款项 | 1,212,353.75 | 3,099 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-066 一、监事会会议召开情况 1、监事会会议通知的时间和方式 关于第八届监事会第四次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）第八届监事会 第四次会议（以下简称"会议"）通知于 2025 年 8 月 18 日以直接送 达、微信等方式送达各位监事。 2、召开监事会会议的时间、地点和方式 会议于 2025 年 8 月 28 日在公司三楼会议室以现场方式召开。 3、监事会会议出席情况 本次会议应参与表决监事 3 人，实际参与表决监事 3 人，公司董 事会秘书及证券事务代表列席会议。 4、会议由监事会主席叶国强先生主持。 浙江亚太药业股份有限公司 经审核，监事会认为：公司本次计提信用减值损失、资产减值损 失事项符合《企业会计准则》等相关文件的规定，符合公司的实际情 1 况，计提后能更加客观公允地反映公司资产状况和经营情况，符合公 司及股东的整体利益。因此，监事会同意公司本次计提信用减值损失、 资产减值损失事项。 具体内容详见 2025 年 ...

浙江亚太药业股份有限公司 2025 年半年度报告全文 浙江亚太药业股份有限公司 2025 年半年度报告 2025 年 08 月 1 浙江亚太药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人岑建维、主管会计工作负责人徐景阳及会计机构负责人(会计 主管人员)徐景阳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。 浙江亚太药业股份有限公司 2025 年半年度报告全文 备查文件目录 1、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表； 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 可能存在行业监管与行业政策变化、药品集中采购等相关风险、产品质量控 制、环保安全、新药研发 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-065 浙江亚太药业股份有限公司 关于第八届董事会第四次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、董事会会议通知的时间和方式 浙江亚太药业股份有限公司（以下简称"公司"）第八届董事会 第四次会议（以下简称"会议"）通知于 2025 年 8 月 18 日以专人送 达、微信等方式送达各位董事。 2、召开董事会会议的时间、地点和方式 会议于 2025 年 8 月 28 日在公司办公楼三楼会议室以现场表决与 通讯表决相结合的方式召开。 3、董事会会议出席情况 公司监事会就该事项发表意见，具体内容详见 2025 年 8 月 30 日 的巨潮资讯网（www.cninfo.com.cn）。 （二）以 9 票同意，0 票反对，0 票弃权，审议通过了《2025 年 半年度报告及其摘要》 本议案已经公司审计委员会审议通过。 本次会议的应表决董事 9 人，实际参与表决董事 9 人，其中董事 宋令波先生以通讯方式参与表决，公司监事、高级管理人员列席会议。 4、会议由董事长 ...